Literature DB >> 32681608

Preoperative Assessment for High-Risk Endometrial Cancer by Developing an MRI- and Clinical-Based Radiomics Nomogram: A Multicenter Study.

Bi Cong Yan1, Ying Li1, Feng Hua Ma2, Feng Feng3, Ming Hua Sun4, Guang Wu Lin5, Guo Fu Zhang2, Jin Wei Qiang1.   

Abstract

BACKGROUND: High- and low-risk endometrial cancer (EC) differ in whether lymphadenectomy is performed. Assessment of high-risk EC is essential for planning surgery appropriately.
PURPOSE: To develop a radiomics nomogram for high-risk EC prediction preoperatively. STUDY TYPE: Retrospective. POPULATION: In all, 717 histopathologically confirmed EC patients (mean age, 56 years ± 9) divided into a primary group (394 patients from Center A), validation groups 1 and 2 (146 patients from Center B and 177 patients from Centers C-E). FIELD STRENGTH/SEQUENCE: 1.5/3T scanners; T2 -weighted imaging, diffusion-weighted imaging, apparent diffusion coefficient, and contrast enhancement sequences. ASSESSMENT: A radiomics nomogram was generated by combining the selected radiomics features and clinical parameters (metabolic syndrome, cancer antigen 125, age, tumor grade following curettage, and tumor size). The area under the curve (AUC) of the receiver operator characteristic was used to evaluate the predictive performance of the radiomics nomogram for high-risk EC. The surgical procedure suggested by the nomogram was compared with the actual procedure performed for the patients. Net benefit of the radiomics nomogram was evaluated by a clinical decision curve (CDC), net reclassification index (NRI), and integrated discrimination improvement (IDI). STATISTICAL TESTS: Binary least absolute shrinkage and selection operator (LASSO) logistic regression, linear regression, and multivariate binary logistic regression were used to select radiomics features and clinical parameters.
RESULTS: The AUC for prediction of high-risk EC for the radiomics nomogram in the primary group, validation groups 1 and 2 were 0.896 (95% confidence interval [CI]: 0.866-0.926), 0.877 (95% CI: 0.825-0.930), and 0.919 (95% CI: 0.879-0.960), respectively. The nomogram achieved good net benefit by CDC analysis for high-risk EC. NRIs were 1.17, 1.28, and 1.51, and IDIs were 0.41, 0.60, and 0.61 in the primary group, validation groups 1 and 2, respectively. DATA
CONCLUSION: The radiomics nomogram exhibited good performance in the individual prediction of high-risk EC, and might be used for surgical management of EC. LEVEL OF EVIDENCE: 4 TECHNICAL EFFICACY STAGE: 2 J. MAGN. RESON. IMAGING 2020;52:1872-1882.
© 2020 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  endometrial cancer; magnetic resonance imaging; nomogram; radiomics; risk stratification

Mesh:

Year:  2020        PMID: 32681608     DOI: 10.1002/jmri.27289

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  12 in total

1.  Radiomics Nomogram in Assisting Lymphadenectomy Decisions by Predicting Lymph Node Metastasis in Early-Stage Endometrial Cancer.

Authors:  Xue-Fei Liu; Bi-Cong Yan; Ying Li; Feng-Hua Ma; Jin-Wei Qiang
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

2.  Multimodal MRI-Based Radiomics-Clinical Model for Preoperatively Differentiating Concurrent Endometrial Carcinoma From Atypical Endometrial Hyperplasia.

Authors:  Jieying Zhang; Qi Zhang; Tingting Wang; Yan Song; Xiaoduo Yu; Lizhi Xie; Yan Chen; Han Ouyang
Journal:  Front Oncol       Date:  2022-05-27       Impact factor: 5.738

3.  MRI-Based Radiomic Model for Preoperative Risk stratification in Stage I Endometrial Cancer.

Authors:  Jingya Chen; Hailei Gu; Weimin Fan; Yaohui Wang; Shuai Chen; Xiao Chen; Zhongqiu Wang
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

4.  Preoperative Assessment for Event-Free Survival With Hepatoblastoma in Pediatric Patients by Developing a CT-Based Radiomics Model.

Authors:  Yi Jiang; Jingjing Sun; Yuwei Xia; Yan Cheng; Linjun Xie; Xia Guo; Yingkun Guo
Journal:  Front Oncol       Date:  2021-04-16       Impact factor: 6.244

Review 5.  Contemporary Fertility-Sparing Management Options of Early Stage Endometrioid Endometrial Cancer in Young Nulliparous Patients.

Authors:  Gulzhanat Aimagambetova; Sanja Terzic; Antonio Simone Laganà; Gauri Bapayeva; Philip la Fleur; Milan Terzic
Journal:  J Clin Med       Date:  2021-12-30       Impact factor: 4.241

6.  Different multiparametric MRI-based radiomics models for differentiating stage IA endometrial cancer from benign endometrial lesions: A multicenter study.

Authors:  Qiu Bi; Yaoxin Wang; Yuchen Deng; Yang Liu; Yuanrui Pan; Yang Song; Yunzhu Wu; Kunhua Wu
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

Review 7.  Endometrial cancer from early to advanced-stage disease: an update for radiologists.

Authors:  Cibele Luna; Patricia Balcacer; Patricia Castillo; Marilyn Huang; Francesco Alessandrino
Journal:  Abdom Radiol (NY)       Date:  2021-07-23

8.  Automatic segmentation of uterine endometrial cancer on multi-sequence MRI using a convolutional neural network.

Authors:  Yasuhisa Kurata; Mizuho Nishio; Yusaku Moribata; Aki Kido; Yuki Himoto; Satoshi Otani; Koji Fujimoto; Masahiro Yakami; Sachiko Minamiguchi; Masaki Mandai; Yuji Nakamoto
Journal:  Sci Rep       Date:  2021-07-14       Impact factor: 4.379

Review 9.  Radiomics in Oncology, Part 2: Thoracic, Genito-Urinary, Breast, Neurological, Hematologic and Musculoskeletal Applications.

Authors:  Damiano Caruso; Michela Polici; Marta Zerunian; Francesco Pucciarelli; Gisella Guido; Tiziano Polidori; Federica Landolfi; Matteo Nicolai; Elena Lucertini; Mariarita Tarallo; Benedetta Bracci; Ilaria Nacci; Carlotta Rucci; Marwen Eid; Elsa Iannicelli; Andrea Laghi
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

10.  A radiogenomics application for prognostic profiling of endometrial cancer.

Authors:  Erling A Hoivik; Erlend Hodneland; Julie A Dybvik; Kari S Wagner-Larsen; Kristine E Fasmer; Hege F Berg; Mari K Halle; Ingfrid S Haldorsen; Camilla Krakstad
Journal:  Commun Biol       Date:  2021-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.